Citizen Petition Watch - Increased Activity Around Ditropan XL

April 2, 2018

There have been two citizen petitions (from two different companies) in the last two working days requesting that the FDA determine that Ditropan XL was not withdrawn from the market for reasons of safety and efficacy. This is a common request made when a generic company wants to submit an ANDA on a reference listed drug (RLD) that has been withdrawn from the market.

It only stands out because of the increased activity on this product that already has seven approved generics for the XL version. Maybe something is going on in the market that is worth considering.

If you want to be alerted to new citizen petitions and have access to our user friendly online petitions database, subscribe here and get our introductory price of only 29.95 per month. You can read more about our citizen petitions database here.

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.